Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI heart scanner could catch silent disease in thousands

NCT ID NCT07351656

Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study is testing whether combining AI-powered electrocardiograms (ECGs) with focused heart ultrasound can effectively screen for heart disease in everyday community settings. Researchers at Mayo Clinic plan to enroll 19,300 people, including teens, adults, and pregnant women. The goal is to see how accurate and practical these tools are for detecting conditions like weak heart muscle, valve problems, and high blood pressure in the lungs, compared to standard tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-Enabled Electrocardiography and Focused Cardiac Ultrasound
What this could lead to
If successful, this could lead to a quick, accurate, and low-cost way to screen large populations for hidden heart disease, catching problems early.
What could go wrong
This is an early feasibility study, not a treatment trial. The AI may produce false positives or miss some conditions, and results may not apply to all groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 19,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Adolescents and young adults: Inclusion Criteria: * Enrollment in a high-school, college or a resident in MN during the study period * Age 18-29 years * Informed consent (and assent for minors) Exclusion Criteria: * Presence of a pacemaker or defibrillator * Inability to obtain a quality ECG tracing Community dwelling adults: Inclusion Criteria: • Adult patients (\>30 years of age, with pre-specified subgroups 30-64 and 65+)) Exclusion Criteria: • Inability to provide informed consent to participate in the study Pregnant women: Inclusion Criteria: * Adult female aged 18 to 49 years * Pregnant at the time of enrollment * Receiving obstetric care at identified study site(s) * Willing and able to provide informed consent Exclusion Criteria: • Inability to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.